| Autor: |
Aboyans, Victor, Bauersachs, Rupert, Mazzolai, Lucia, Brodmann, Marianne, Palomares, José F Rodriguez, Debus, Sebastian, Collet, Jean-Philippe, Drexel, Heinz, Espinola-Klein, Christine, Lewis, Basil S, Roffi, Marco, Sibbing, Dirk, Sillesen, Henrik, Stabile, Eugenio, Schlager, Oliver, Carlo, Marco De |
| Předmět: |
|
| Zdroj: |
European Heart Journal; 10/14/2021, Vol. 42 Issue 39, p4013-4024, 12p |
| Abstrakt: |
The aim of this collaborative document is to provide an update for clinicians on best antithrombotic strategies in patients with aortic and/or peripheral arterial diseases. Antithrombotic therapy is a pillar of optimal medical treatment for these patients at very high cardiovascular risk. While the number of trials on antithrombotic therapies in patients with aortic or peripheral arterial diseases is substantially smaller than for those with coronary artery disease, recent evidence deserves to be incorporated into clinical practice. In the absence of specific indications for chronic oral anticoagulation due to concomitant cardiovascular disease, a single antiplatelet agent is the basis for long-term antithrombotic treatment in patients with aortic or peripheral arterial diseases. Its association with another antiplatelet agent or low-dose anticoagulants will be discussed, based on patient's ischaemic and bleeding risk as well therapeutic paths (e.g. endovascular therapy). This consensus document aims to provide a guidance for antithrombotic therapy according to arterial disease localizations and clinical presentation. However, it cannot substitute multidisciplinary team discussions, which are particularly important in patients with uncertain ischaemic/bleeding balance. Importantly, since this balance evolves over time in an individual patient, a regular reassessment of the antithrombotic therapy is of paramount importance. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
